+publisher:"University of Illinois – Chicago" +contributor:("Schumock, Glen T")

University of Illinois – Chicago

1. Lee, Wan-Ju. Utilization and Risk of Serious Infection Associated with TNF-α Inhibitors in Children and Young Adults.

Degree: 2016, University of Illinois – Chicago

URL: http://hdl.handle.net/10027/21614

► This dissertation examined use of tumor necrosis factor-alpha inhibitors (TNFI) and risk of TNFI-associated serious infection compared to oral immunosuppressants in children and young adults… (more)

▼ This dissertation examined use of tumor necrosis factor-alpha inhibitors (TNFI) and risk of TNFI-associated serious infection compared to oral immunosuppressants in children and young adults with juvenile idiopathic arthritis (JIA)/rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Four retrospective cohort studies were conducted using the Truven Health MarketScan Research Database (2009-2013). TNFI treatment patterns, early TNFI therapy rates, and time to TNFI initiation were examined in incident JIA/RA and IBD cohorts. Serious infections were defined as those requiring hospitalization. Cox proportional hazard models were used to estimate the risk of serious infection associated with TNFIs in JIA and IBD cohorts. High-dimensional propensity score models were used to control for potential confounding. In two studies examining treatment patterns, 18.6% of the incident JIA/RA cohort initiated TNFIs, and etanercept was most commonly used, while in the incident IBD cohort, 27.6% initiated TNFIs, and infliximab was most commonly used. In both cohorts, time from new diagnosis to first TNFI prescription was shorter in more recent years. Specifically, early TNFI therapy increased over time in the IBD cohort. In a third study, 2,495 JIA patients were followed for 1,810 person-years. Serious infection rates were 2.7/100 person-years for TNFIs and 1.28/100 person-years for disease-modifying antirheumatic drugs (DMARD). TNFI monotherapy posed a 2.7-fold increase in risk of serious infection compared to DMARDs alone. In the fourth study, 10,838 IBD patients were followed for 9,849 person-years. Serious infection rates were 5.25/100 person-years for TNFIs and 3.59/100 person-years for immunomodulators (methotrexate and thiopurines). New use of TNFI monotherapy was associated with a 1.36-fold higher risk of serious infection compared to immunomodulator initiation. The risk of serious infection differed by individual TNFIs and route of administration. This dissertation characterized the utilization of TNFIs and indicated that a more aggressive treatment approach has emerged for children and young adults with JIA/RA and IBD despite an FDA warning about TNFI-associated serious infections. However, study findings support the warning for children with JIA and IBD. This dissertation provides insights into how TNFIs are being used and informs decision-making about use of these drugs–particularly regarding balancing the benefits and risks of TNFIs. Advisors/Committee Members: Schumock, Glen T (advisor), Lee, Todd A (committee member), Calip, Gregory S (committee member), Suda, Katie J (committee member), Briars, Leslie (committee member), Schumock, Glen T (chair).

Subjects/Keywords: TNF inhibitors; infections

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Lee, W. (2016). Utilization and Risk of Serious Infection Associated with TNF-α Inhibitors in Children and Young Adults. (Thesis). University of Illinois – Chicago. Retrieved from http://hdl.handle.net/10027/21614

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Lee, Wan-Ju. “Utilization and Risk of Serious Infection Associated with TNF-α Inhibitors in Children and Young Adults.” 2016. Thesis, University of Illinois – Chicago. Accessed January 24, 2021. http://hdl.handle.net/10027/21614.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Lee, Wan-Ju. “Utilization and Risk of Serious Infection Associated with TNF-α Inhibitors in Children and Young Adults.” 2016. Web. 24 Jan 2021.

Vancouver:

Lee W. Utilization and Risk of Serious Infection Associated with TNF-α Inhibitors in Children and Young Adults. [Internet] [Thesis]. University of Illinois – Chicago; 2016. [cited 2021 Jan 24]. Available from: http://hdl.handle.net/10027/21614.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Lee W. Utilization and Risk of Serious Infection Associated with TNF-α Inhibitors in Children and Young Adults. [Thesis]. University of Illinois – Chicago; 2016. Available from: http://hdl.handle.net/10027/21614

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Illinois – Chicago

2. Adimadhyam, Sruthi. Comparative Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.

Degree: 2018, University of Illinois – Chicago

URL: http://hdl.handle.net/10027/23328

► More than 30 million people living in the US have diabetes. Over time, increased concentrations of glucose in the blood lead to cellular damage and… (more)

▼ More than 30 million people living in the US have diabetes. Over time, increased concentrations of glucose in the blood lead to cellular damage and cause a variety of serious complications in these individuals. Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) are the latest class of oral antidiabetic medications approved for use in the US. They work by blocking the resorption of glucose in the kidney thereby increasing urinary glucose excretion. Due to their distinct mechanism of action, these drugs demonstrate cardio- and reno-protective effects in addition to their antihyperglycemic effect. However, clinical trials report an increased risk for adverse events such as amputations, fractures, and mycotic infections raising concerns about their safety. The objective of this dissertation was to evaluate the comparative safety of these drugs in a real-world setting outside of clinical trials. Three observational studies were conducted using prescription and medical insurance data from Truven Health MarketScan Databases (2009-2015). The first study investigated the association between SGLT2i and amputations and concluded that the potential for harm cannot be ruled out. While there was a 38% increase in risk for amputations following initiation of treatment with SGLT2i, the 95% confidence interval included the null. The second study investigated the association between SGLT2i and fractures. There was an 82% increase in risk for fractures early in treatment with SGLT2i. Beyond the initial 2-week treatment period, there was no apparent effect on fracture risk. The third study investigated the association between SGLT2i and mycotic infections. There was a 53% increase in risk for mycotic infections within the first 90 days of treatment with SGLT2i. This dissertation evaluated the post-marketing safety of this new class of antidiabetic medications in a real-world setting. Evidence from such observational studies can supplement that from clinical trials to more thoroughly inform decision-making. Findings from this research can help clinicians understand patients at high-risk for experiencing these events and devise remedial measures in anticipation. Advisors/Committee Members: Schumock, Glen T (advisor), Lee, Todd A (committee member), Calip, Gregory S (committee member), Smith Marsh, Daphne E (committee member), Layden, Brian T (committee member), Schumock, Glen T (chair).

Subjects/Keywords: pharmacoepidemiology; drug safety; SGLT2 inhibitors; type 2 diabetes; amputations; fractures; mycotic infections

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Adimadhyam, S. (2018). Comparative Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. (Thesis). University of Illinois – Chicago. Retrieved from http://hdl.handle.net/10027/23328

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Adimadhyam, Sruthi. “Comparative Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.” 2018. Thesis, University of Illinois – Chicago. Accessed January 24, 2021. http://hdl.handle.net/10027/23328.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Adimadhyam, Sruthi. “Comparative Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.” 2018. Web. 24 Jan 2021.

Vancouver:

Adimadhyam S. Comparative Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. [Internet] [Thesis]. University of Illinois – Chicago; 2018. [cited 2021 Jan 24]. Available from: http://hdl.handle.net/10027/23328.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Adimadhyam S. Comparative Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. [Thesis]. University of Illinois – Chicago; 2018. Available from: http://hdl.handle.net/10027/23328

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Illinois – Chicago

3. Drozda, Katarzyna. Warfarin Pharmacogenomic Implementation: Implications for Minorities and Opportunities for Education.

Degree: 2014, University of Illinois – Chicago

URL: http://hdl.handle.net/10027/19063

► Recent clinical trial results cast doubt on the utility of genotype-guided warfarin dosing, specifically showing worse dosing with a pharmacogenetic versus clinical dosing algorithm in… (more)

Subjects/Keywords: Pharmacogenomics; warfarin; genotype; CYP2C9; rs12777823

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Drozda, K. (2014). Warfarin Pharmacogenomic Implementation: Implications for Minorities and Opportunities for Education. (Thesis). University of Illinois – Chicago. Retrieved from http://hdl.handle.net/10027/19063

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Drozda, Katarzyna. “Warfarin Pharmacogenomic Implementation: Implications for Minorities and Opportunities for Education.” 2014. Thesis, University of Illinois – Chicago. Accessed January 24, 2021. http://hdl.handle.net/10027/19063.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Drozda, Katarzyna. “Warfarin Pharmacogenomic Implementation: Implications for Minorities and Opportunities for Education.” 2014. Web. 24 Jan 2021.

Vancouver:

Drozda K. Warfarin Pharmacogenomic Implementation: Implications for Minorities and Opportunities for Education. [Internet] [Thesis]. University of Illinois – Chicago; 2014. [cited 2021 Jan 24]. Available from: http://hdl.handle.net/10027/19063.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Drozda K. Warfarin Pharmacogenomic Implementation: Implications for Minorities and Opportunities for Education. [Thesis]. University of Illinois – Chicago; 2014. Available from: http://hdl.handle.net/10027/19063

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Illinois – Chicago

4. Patel, Vardhaman. Direct Thrombin Inhibitors: Use and Consequences in Patients with Heparin-Induced Thrombocytopenia.

Degree: 2015, University of Illinois – Chicago

URL: http://hdl.handle.net/10027/19794

► Heparin-induced thrombocytopenia (HIT) is an immunologic response to heparin exposure that may lead to thrombosis. Argatroban and bivalirudin are two commonly used direct thrombin inhibitors… (more)

▼ Heparin-induced thrombocytopenia (HIT) is an immunologic response to heparin exposure that may lead to thrombosis. Argatroban and bivalirudin are two commonly used direct thrombin inhibitors (DTIs) for the prevention of thrombosis in patients with HIT. However, DTIs may lead to major bleeding events. Data on the use and consequences of DTIs is limited. Of note, patients with suspected HIT are of interest in the thesis, as current guidelines recommend the initiation of DTI treatment at the time of clinical suspicion of HIT. This thesis focused on the identification of suspected HIT, and the use and consequences of direct thrombin inhibitors (DTI) for the treatment of suspected HIT. First, algorithms based on diagnostic codes, medications and diagnostic tests were developed and validated to identify patients with suspected HIT. An algorithm based only on the timing of medication and diagnostic tests was recommended for the identification of suspected HIT from claims data, as it was observed to have the highest positive predictive value and sensitivity. Second, the rates of thrombosis, major bleeding, amputation and mortality were compared between argatroban-treated and bivalirudin-treated patients using administrative claims data obtained from the University HealthSystem Consortium. The difference in the likelihood of thrombosis, amputation and mortality between the two DTI groups was not statistically significant. However, bivalirudin-treated patients were more likely to experience major bleeding than argatroban-treated patients. Third, the use of bivalirudin for the treatment of suspected HIT (off-label use) increased from one-third to half of DTI-treated patients from 2010 to 2012. Patients treated by surgeons or specialists were more likely to receive off-label bivalirudin compared to patients treated by primary care. In addition, hepatic impairment and skin infection increased the odds of patients to receive bivalirudin over argatroban. In conclusion, the off-label use of bivalirudin should be scrutinized for medical necessity due to the higher risk of bleeding than argatroban, except in patients with hepatic impairment. Advisors/Committee Members: Walton, Surrey M. (advisor), Schumock, Glen T. (committee member), Lee, Todd A. (committee member), Galanter, William L. (committee member), Nutescu, Edith A. (committee member), Hohmann, Samuel F. (committee member).

Subjects/Keywords: 1; comparative effectiveness; 2; direct thrombin inhibitors; 3; argatroban; 4; bivalirudin; 5; thrombosis; 6; major bleeding; 7; safety; 8; off-label; 9; algorithms; 10; validity

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Patel, V. (2015). Direct Thrombin Inhibitors: Use and Consequences in Patients with Heparin-Induced Thrombocytopenia. (Thesis). University of Illinois – Chicago. Retrieved from http://hdl.handle.net/10027/19794

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Patel, Vardhaman. “Direct Thrombin Inhibitors: Use and Consequences in Patients with Heparin-Induced Thrombocytopenia.” 2015. Thesis, University of Illinois – Chicago. Accessed January 24, 2021. http://hdl.handle.net/10027/19794.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Patel, Vardhaman. “Direct Thrombin Inhibitors: Use and Consequences in Patients with Heparin-Induced Thrombocytopenia.” 2015. Web. 24 Jan 2021.

Vancouver:

Patel V. Direct Thrombin Inhibitors: Use and Consequences in Patients with Heparin-Induced Thrombocytopenia. [Internet] [Thesis]. University of Illinois – Chicago; 2015. [cited 2021 Jan 24]. Available from: http://hdl.handle.net/10027/19794.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Patel V. Direct Thrombin Inhibitors: Use and Consequences in Patients with Heparin-Induced Thrombocytopenia. [Thesis]. University of Illinois – Chicago; 2015. Available from: http://hdl.handle.net/10027/19794

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Illinois – Chicago

5. Monberg, Matthew J. Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers.

Degree: 2016, University of Illinois – Chicago

URL: http://hdl.handle.net/10027/20886

► Background: Although head and neck cancer (HNC) is the sixth most common cancer type by incidence globally, few studies have focused on real world treatment… (more)

▼ Background: Although head and neck cancer (HNC) is the sixth most common cancer type by incidence globally, few studies have focused on real world treatment patterns of this disease. A large, randomized study of erythropoietin stimulating agents (ESAs) produced worsened outcomes in patients with HNC. Real-world data on the treatment patterns HNC, and the use and outcomes of ESAs in this population is currently lacking. Methods: SEER Medicare was used to evaluate patients aged ≥65 years with a first diagnosis of HNC between 2002 and 2007. Logistic regression was used to evaluate predictors of treatment. An interrupted time series was used to estimate the changes in ESA use among patients receiving chemotherapy over time. Propensity weighted models predicted survival, thromboembolism (TEE), and disease recurrence outcomes associated with ESA exposure. Results: Characteristics associated with no treatment for HNC included being unmarried (adjusted OR=2.00, 95% CI: 1.75, 2.27) or African American (adjusted OR=1.65, 95% CI: 1.37, 1.98). ESA use was 50.0% among patients receiving chemotherapy and 3.1% among patients not receiving chemotherapy. ESA use was 50.0% among patients receiving chemotherapy and 3.1% among patients not receiving chemotherapy. Combination regimens such as cetuximab+taxane+platinum (63.8%) and taxane+platinum (56.0%) were associated with the highest rates of ESA use, while single-agent cetuximab was associated with the lowest rate of ESA use (22.3%). Use of ESAs significantly declined from 40.3% of patients receiving chemotherapy in January 2007 to 16.7% in August 2007. Patients receiving an ESA were more likely to have a TEE (adjusted HR=1.19 [95% CI: 1.31, 1.81), experience disease recurrence (adjusted HR=1.09 [95% CI: 1.00, 1.16]), or die (adjusted HR=1.17 [95% CI: 1.06, 1.30]). Discussion: Disparities in the diagnosis and treatment of patients with HNC were present, despite the uniform insurance status of patients in the database. Significant declines in ESA occurred following FDA action in January 2007. ESA use increased among HNC patients in the immediate aftermath of previous disclosure of negative trial data (June 2003). ESAs may be associated with modestly worsened outcomes in HNC. Advisors/Committee Members: Stayner, Leslie T. (advisor), Lee, Todd A. (committee member), Rauscher, Garth H. (committee member), Reda, Domenic J. (committee member), Schumock, Glen T. (committee member), Zinner, Ralph G. (committee member).

Subjects/Keywords: SEER Medicare; head and neck cancer; HNC; erythropoietin stimulating agents; anemia; supportive care; ESAs; cetuximab; disparities; chemotherapy; radiation

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Monberg, M. J. (2016). Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers. (Thesis). University of Illinois – Chicago. Retrieved from http://hdl.handle.net/10027/20886

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Monberg, Matthew J. “Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers.” 2016. Thesis, University of Illinois – Chicago. Accessed January 24, 2021. http://hdl.handle.net/10027/20886.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Monberg, Matthew J. “Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers.” 2016. Web. 24 Jan 2021.

Vancouver:

Monberg MJ. Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers. [Internet] [Thesis]. University of Illinois – Chicago; 2016. [cited 2021 Jan 24]. Available from: http://hdl.handle.net/10027/20886.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Monberg MJ. Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers. [Thesis]. University of Illinois – Chicago; 2016. Available from: http://hdl.handle.net/10027/20886

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Illinois – Chicago

6. Jalundhwala, Yash J. The Role of Health-Related Lifestyle Attitudes in Understanding Health Behaviors and Outcomes.

Degree: 2016, University of Illinois – Chicago

URL: http://hdl.handle.net/10027/21586

► Health systems throughout the world increasingly recognize health-related quality of life (HRQoL) as a key patient-centered health outcome. HRQoL is particularly important in conditions which… (more)

▼ Health systems throughout the world increasingly recognize health-related quality of life (HRQoL) as a key patient-centered health outcome. HRQoL is particularly important in conditions which impair daily living (e.g. Parkinson’s Disease) and in those that are largely subjective in nature (e.g. pain). HRQoL, when assessed using a preference-based measure, is an essential component in the calculation of quality adjusted life years (QALYs). QALYs gained form the denominator in an incremental cost-effectiveness ratio (ICER), which is the most common result derived in a cost-utility analysis and is used to inform patient and system-level decisions and incorporated into pricing and reimbursement decisions. HRQoL can be viewed as an individual’s perception of his/her own health. An individual’s perception is often influenced by attitudes and beliefs, which in turn also influence health behaviors and overall health. This dissertation examines the role of health and life-style related attitudes (HLA) in understanding health behaviors and outcomes through three separate studies. The studies evaluated the validity of measures of HRQoL and HLA in a community population and examined the relationship between HLA and health behaviors, self-assessment of health and life-satisfaction. The first chapter introduces key study concepts including HLA, self-assessment and life-satisfaction along with a conceptual framework that facilitates the understanding of the relationship between HLA, health behaviors and outcomes (including self-assessment of health and life satisfaction). The introductory chapter highlights the gaps in the evidence, research objectives and hypotheses that were examined in subsequent chapters, and explains the significance of the research. All the studies are based on secondary analyses from a large scale community health study conducted in Kirklees, United Kingdom, in 2012. The second chapter examines the properties of the recently developed EQ-5D-5L as a measure of population health in a large community-based survey. The assessment of the construct validity of the EQ-5D-5L in a community sample helps to facilitate in the use of EQ-5D-5L in general population health studies. A secondary aim of the study was to compare EQ-5D-5L summary scores based on an English value set (5L-ENG), crosswalk scores based on 3L values (XW), and scores based on equal weighting (5L-EWS). Properties of the EQ-5D-5L that were examined included discriminative ability, strength of correlations with related measures of health, and statistical efficiency, as assessed with relative efficiency (RE) ratios between summary scores from known group comparisons, using the XW as the referent. Correlations between EQ-5D dimensions and other measures of health ranged from r =0.56-0.73. Compared to the XW, the RE of the 5L-ENG and 5L-EWS were similar or higher (Age:RE5L-ENG=0.96,RE5L-EWS=1.36; BMI:RE5L-ENG=1.00,RE5L-EWS=1.0; Number of prescription medications:RE5L-ENG=1.00,RE5L-EWS=1.18; Number of Chronic conditions:RE5L-ENG=1.00,RE5L-EWS=1.61; General… Advisors/Committee Members: Pickard , Simon A (advisor), Walton , Surrey M (committee member), Schumock , Glen T (committee member), Sharp , Lisa K (committee member), Caskey , Rachel K (committee member), Pickard , Simon A (chair).

Subjects/Keywords: health-related quality of life; health attitudes

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Jalundhwala, Y. J. (2016). The Role of Health-Related Lifestyle Attitudes in Understanding Health Behaviors and Outcomes. (Thesis). University of Illinois – Chicago. Retrieved from http://hdl.handle.net/10027/21586

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Jalundhwala, Yash J. “The Role of Health-Related Lifestyle Attitudes in Understanding Health Behaviors and Outcomes.” 2016. Thesis, University of Illinois – Chicago. Accessed January 24, 2021. http://hdl.handle.net/10027/21586.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Jalundhwala, Yash J. “The Role of Health-Related Lifestyle Attitudes in Understanding Health Behaviors and Outcomes.” 2016. Web. 24 Jan 2021.

Vancouver:

Jalundhwala YJ. The Role of Health-Related Lifestyle Attitudes in Understanding Health Behaviors and Outcomes. [Internet] [Thesis]. University of Illinois – Chicago; 2016. [cited 2021 Jan 24]. Available from: http://hdl.handle.net/10027/21586.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Jalundhwala YJ. The Role of Health-Related Lifestyle Attitudes in Understanding Health Behaviors and Outcomes. [Thesis]. University of Illinois – Chicago; 2016. Available from: http://hdl.handle.net/10027/21586

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Illinois – Chicago

7. Samp, Jennifer C. Comparative Efficacy and Safety of Combination Treatments for Chronic Obstructive Pulmonary Disease.

Degree: 2017, University of Illinois – Chicago

URL: http://hdl.handle.net/10027/21925

► Background: Treatment with a long-acting beta2-agonist (LABA) is an integral part of the guidelines for management of chronic obstructive pulmonary disease (COPD). Concurrent use of… (more)

▼ Background: Treatment with a long-acting beta2-agonist (LABA) is an integral part of the guidelines for management of chronic obstructive pulmonary disease (COPD). Concurrent use of a LABA and a long-acting muscarinic antagonist (LAMA) are believed to enhance bronchodilation due to the synergistic mechanisms of action. Only recently have fixed dose combination LABA/LAMA agents been developed which has resulted in a vast amount of efficacy and safety data from clinical trials. However, data remains lacking on the effectiveness and safety of LABA/LAMA in a broader population of COPD patients. Objectives: The aims of this research were to examine real-world effectiveness and safety of LABA/LAMA compared to LABA/inhaled corticosteroid (LABA/ICS) combination treatment. A secondary goal was to develop a predictive model to identify those at risk for COPD exacerbations among patients treated with LABA/LAMA or LABA/ICS. Methods: This was a retrospective, observational study utilizing administrative claims data among COPD patients initiating LABA/LAMA or LABA/ICS. Effectiveness was measured by comparing COPD exacerbation rates using Poisson regression models adjusted for baseline covariates. We examined cardiovascular and cerebrovascular safety outcomes by measuring hospitalizations with a primary diagnosis for acute coronary syndrome, heart failure, cardiac dysrhythmia, stroke, or transient ischemic attack. Time to event was compared using Cox proportional hazards models after matching patients 1 LABA/LAMA user to 4 LABA/ICS users) on propensity score. A predictive model of COPD exacerbations among LABA/LAMA or LABA/ICS users was developed using stepwise logistic regression in a training set of the original cohort. The test characteristics of the model were evaluated in the training set and validation set of patients. Results: Patients treated with the LABA/LAMA combination had similar exacerbation rates compared to those treated with LABA/ICS (adjusted incidence rate ratio of 0.98 [95% CI: 0.95 – 1.01]). Cardiovascular events in the LABA/LAMA cohort were lower than LABA/ICS (hazard ratio [HR]=0.794 [95% CI: 0.623-0.997]) but there was no significant difference in the risk of cerebrovascular events (HR=1.166 [95% CI 0.653-1.959]). The base predictive model resulted in a sensitivity of 41.6% and specificity of 85.5%. Other exploratory models resulted in similar test characteristics. Conclusions: In this real-world, observational study, exacerbations rates and cerebrovascular events were similar among patients treated with LABA/LAMA and LABA/ICS. Patients treated with LABA/LAMA had slightly lower risk of cardiovascular events. Further studies are recommended to confirm these findings. Finally, we were not able to develop a predictive model that identified patients at high risk for COPD exacerbations among patients treated with LABA/LAMA or LABA/ICS. Advisors/Committee Members: Lee, Todd A (advisor), Joo, Min J (committee member), Schumock, Glen T (committee member), Pickard, A S (committee member), Calip, Gregory S (committee member), Lee, Todd A (chair).

Subjects/Keywords: Chronic obstructive pulmonary disease

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Samp, J. C. (2017). Comparative Efficacy and Safety of Combination Treatments for Chronic Obstructive Pulmonary Disease. (Thesis). University of Illinois – Chicago. Retrieved from http://hdl.handle.net/10027/21925

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Samp, Jennifer C. “Comparative Efficacy and Safety of Combination Treatments for Chronic Obstructive Pulmonary Disease.” 2017. Thesis, University of Illinois – Chicago. Accessed January 24, 2021. http://hdl.handle.net/10027/21925.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Samp, Jennifer C. “Comparative Efficacy and Safety of Combination Treatments for Chronic Obstructive Pulmonary Disease.” 2017. Web. 24 Jan 2021.

Vancouver:

Samp JC. Comparative Efficacy and Safety of Combination Treatments for Chronic Obstructive Pulmonary Disease. [Internet] [Thesis]. University of Illinois – Chicago; 2017. [cited 2021 Jan 24]. Available from: http://hdl.handle.net/10027/21925.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Samp JC. Comparative Efficacy and Safety of Combination Treatments for Chronic Obstructive Pulmonary Disease. [Thesis]. University of Illinois – Chicago; 2017. Available from: http://hdl.handle.net/10027/21925

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Illinois – Chicago

8. Xing, Shan. Second Generation Antipsychotics and Diabetes Outcomes in Patients with Depression and Diabetes.

Degree: 2017, University of Illinois – Chicago

URL: http://hdl.handle.net/10027/22207

► This dissertation evaluated the use of and comparative effects of second generation antipsychotics (SGAs) and non-SGA depression pharmacotherapies [bupropion, lithium, mirtazapine, tricyclic antidepressants (TCAs) and… (more)

▼ This dissertation evaluated the use of and comparative effects of second generation antipsychotics (SGAs) and non-SGA depression pharmacotherapies [bupropion, lithium, mirtazapine, tricyclic antidepressants (TCAs) and thyroid hormone] on diabetes outcomes in patients with pre-existing diabetes and depression who previously used a selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor. Three clinical studies compared 1) non-adherence and non-persistence to SGA versus non-SGA depression therapies, 2) non-adherence and non-persistence to oral antidiabetic drugs (OAD) between SGA and non-SGA users, and 3) SGA and non-SGA users on the risk of diabetes-related hospitalization or diabetes drug intensification. Use of SGAs was associated with a 1.8 times higher odds of non-adherence and a 1.4 times higher risk of non-persistence to therapy compared to non-SGA use. Also, SGA users had a 30-40% higher odds of a 10% or greater decline in OAD adherence compared to non-SGA users, while persistence to OAD therapy was similar between groups. Risk of diabetes of diabetes-related hospitalization or diabetes drug intensification was no different comparing SGA versus non-SGA users; however, there were differences when comparing specific treatment subgroups: bupropion was associated with a 15% reduced risk of diabetes-related hospitalization or treatment intensification compared to TCAs, quetiapine was associated with a 18% reduced risk of events compared to mirtazapine, and quetiapine was associated with a 16% reduced risk of events compared to TCAs. Differences for other subgroup comparisons between aripiprazole, quetiapine, bupropion, mirtazapine and TCAs were small and non-significant. Future studies are needed to access the impact of SGA and non-SGA therapies on other diabetes outcomes, including hemoglobin A1c, diabetic complications, and mortality. A fourth methodological study assessed the performance of full-cohort high dimensional propensity score (HDPS) matching approaches versus subgroup-specific HDPS approaches. The full-cohort HDPS matching approaches sometimes resulted in non-overlapping propensity score distributions, more imbalance in potential confounders, and greater than 10% change in effect estimates compared to the subgroup-specific approach. Therefore, examining covariate balance after matching to ensure that patient subgroups are balanced with respect to potential confounders is recommended if one of the full-cohort HDPS approaches are used. Advisors/Committee Members: Lee, Todd A (advisor), Calip, Gregory S (committee member), Leow, Alex D (committee member), Kim, Shiyun (committee member), Schumock, Glen T (committee member), Touchette, Daniel R (committee member), Lee, Todd A (chair).

Subjects/Keywords: Antipsychotic Agents High dimensional propensity score Depression Diabetes Comorbidity Pharmacoepidemiology

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Xing, S. (2017). Second Generation Antipsychotics and Diabetes Outcomes in Patients with Depression and Diabetes. (Thesis). University of Illinois – Chicago. Retrieved from http://hdl.handle.net/10027/22207

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Xing, Shan. “Second Generation Antipsychotics and Diabetes Outcomes in Patients with Depression and Diabetes.” 2017. Thesis, University of Illinois – Chicago. Accessed January 24, 2021. http://hdl.handle.net/10027/22207.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Xing, Shan. “Second Generation Antipsychotics and Diabetes Outcomes in Patients with Depression and Diabetes.” 2017. Web. 24 Jan 2021.

Vancouver:

Xing S. Second Generation Antipsychotics and Diabetes Outcomes in Patients with Depression and Diabetes. [Internet] [Thesis]. University of Illinois – Chicago; 2017. [cited 2021 Jan 24]. Available from: http://hdl.handle.net/10027/22207.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Xing S. Second Generation Antipsychotics and Diabetes Outcomes in Patients with Depression and Diabetes. [Thesis]. University of Illinois – Chicago; 2017. Available from: http://hdl.handle.net/10027/22207

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Illinois – Chicago

9. Harrington, Rachel L. Multimorbidity and Condition Clustering in Children & Adolescents: Resource Use, Expenditures & Quality.

Degree: 2019, University of Illinois – Chicago

URL: http://hdl.handle.net/10027/23689

► The goal of this dissertation was to describe the patterns of multimorbidity among children in the United States, and to examine the role multimorbidity plays… (more)

▼ The goal of this dissertation was to describe the patterns of multimorbidity among children in the United States, and to examine the role multimorbidity plays in pediatric healthcare resource utilization and quality of care. This work was conceptualized and executed as four separate studies, two in the general pediatric population, and two among early survivors of pediatric cancer (children under 18 who were a minimum of 2 years out from end of active therapy). All studies were conducted in a national, commercially-insured, cohort of children identified in the Truven Marketscan Commercial Claims and Encounters Database (2009-2014). The first study examined healthcare resource utilization associated with multimorbidity among children with chronic illness. Latent class analysis was used to identify eight comorbidity groups. The “Attention Deficit” group was the largest (22.1%), while the highest resource utilization was observed among children belonging to the “Developmental Disorder” group (mean annual expenditures of 24,606). The second study examined differences in quality of care in the same population. Only 55% of children achieved quality benchmarks (scores ≥75%). Compared to children with one chronic condition, the lowest quality was experienced by the “Mood Disorders” group (Odds Ratio [OR]: 0.6, Confidence Interval [CI]: 0.5-0.6), while highest was the “Chronic Otitis Media” group (OR: 1.9, CI: 1.9-2.0). The third study focused on early survivors of pediatric cancer, the number of chronic conditions they experienced, and associated resource utilization. Over 20% of survivors had at least one chronic condition, and 36.3% had multiple. Compared to survivors without chronic conditions, the presence of multimorbidity significantly increased the odds of an emergency department visit (OR: 1.7, CI: 1.4-2.1), and of a hospitalization (OR: 3.8, CI: 2.5-5.5). The fourth study built on this work by identifying five comorbidity groups among the early survivor population to further explore differences in utilization. Compared to survivors without chronic conditions, membership in the “Central Nervous System” (CNS) group was significantly associated with the highest expenditures (25,370), while membership in “CNS with Endocrine” had the highest odds of hospitalization (OR: 5.0, CI: 2.3-10.7). Overall, this dissertation provides a new way of conceptualizing and evaluating the burden of chronic conditions in the pediatric population. By linking epidemiologic, resource utilization and quality evidence in this population, results of this work highlight the existence of subgroups of children for whom additional clinical care and policy interventions may be warranted in the current environment of value-based healthcare. Advisors/Committee Members: Lee, Todd A (advisor), Schumock, Glen T (committee member), Qato, Dima M (committee member), Antoon, James W (committee member), Caskey, Rachel N (committee member), Lee, Todd A (chair).

Subjects/Keywords: multimorbidity; children; pediatric; cancer survivorship; quality of care; healthcare utilization

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Harrington, R. L. (2019). Multimorbidity and Condition Clustering in Children & Adolescents: Resource Use, Expenditures & Quality. (Thesis). University of Illinois – Chicago. Retrieved from http://hdl.handle.net/10027/23689

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Harrington, Rachel L. “Multimorbidity and Condition Clustering in Children & Adolescents: Resource Use, Expenditures & Quality.” 2019. Thesis, University of Illinois – Chicago. Accessed January 24, 2021. http://hdl.handle.net/10027/23689.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Harrington, Rachel L. “Multimorbidity and Condition Clustering in Children & Adolescents: Resource Use, Expenditures & Quality.” 2019. Web. 24 Jan 2021.

Vancouver:

Harrington RL. Multimorbidity and Condition Clustering in Children & Adolescents: Resource Use, Expenditures & Quality. [Internet] [Thesis]. University of Illinois – Chicago; 2019. [cited 2021 Jan 24]. Available from: http://hdl.handle.net/10027/23689.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Harrington RL. Multimorbidity and Condition Clustering in Children & Adolescents: Resource Use, Expenditures & Quality. [Thesis]. University of Illinois – Chicago; 2019. Available from: http://hdl.handle.net/10027/23689

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

		in
And / Or
		in
And / Or
		in
And / Or
		in

Open Access Theses and Dissertations